Eledon is dedicated to “One Transplant For Life” to significantly improve both the longevity of the organ and the overall health and quality of life for transplant recipients so that a donor’s greatest gift will keep on giving.
Our lead compound is tegoprubart, an anti-CD40L antibody with broad therapeutic potential to regulate the drivers that can lead to the immune system attacking and rejecting transplanted organs.
Tegoprubart Clinical Development
Eledon has completed BESTOW, a global Phase 2 clinical trial evaluating tegoprubart for the prevention of kidney transplant rejection in first-time allograft recipients. Participants completing BESTOW are eligible to enroll in an ongoing global open-label extension study to evaluate the long-term efficacy and safety of tegoprubart.
In parallel, Eledon is conducting an ongoing single-arm Phase 1b clinical trial of tegoprubart for the prevention of rejection in persons receiving a kidney transplant. Eledon is also currently evaluating tegoprubart’s potential in other types of organ transplantation, including liver transplantation and xenotransplantation.
“There has been little innovation in immunomodulatory therapy for organ transplants since the approval of tacrolimus 30 years ago. Organ transplant recipients deserve better. Targeting the CD40 Ligand pathway may provide significant advantages over current treatment options, including the ability to more effectively control immune response and increase transplant durability.”
Steven Perrin, Ph.D., President and Chief Scientific Officer, shares insights on important advances in immunosuppression and xenotransplantation that are shaping the future of transplant care.
